Lb Pharmaceuticals Inc is a late stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric disorders including schizophrenia bipolar depression adjunctive treatment of major depressive disorder and other diseases. The company s lead product candidate LB 102 is a methylated derivative of amisulpride designed to improve blood brain barrier penetration and enable lower once daily dosing. LB 102 is currently in late stage clinical…
Lb Pharmaceuticals Inc is a late stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric disorders including schizophrenia bipolar depression adjunctive treatment of major depressive disorder and other diseases. The company s lead product candidate LB 102 is a methylated derivative of amisulpride designed to improve blood brain barrier penetration and enable lower once daily dosing. LB 102 is currently in late stage clinical development for schizophrenia and bipolar depression with plans to evaluate it as an adjunctive treatment for major depressive disorder.
We do not currently generate product revenue as we are focused on the research and development of LB 102. Our future revenue will depend on obtaining regulatory approval for LB 102 and subsequent commercial sales of the drug in the United States and other markets. If approved we expect to derive revenue from the sale of oral and long acting injectable formulations of LB 102 to healthcare providers and patients.
Lb Pharmaceuticals Inc positions itself as a potential first mover in the United States antipsychotic market with its benzamide class candidate LB 102 which aims to address unmet needs in schizophrenia bipolar depression and major depressive disorder. The company differentiates LB 102 through improved blood brain barrier penetration lower dosing frequency and a favorable tolerability profile compared with existing antipsychotics such as Vraylar Rexulti Caplyta and Cobenfy. These attributes are intended to provide better adherence and reduced side effects which could give LB 102 a competitive edge in a market where several branded antipsychotic drugs each generate over one billion dollars in annual United States sales.
The company intends to serve patients suffering from schizophrenia bipolar depression and major depressive disorder as well as the healthcare providers hospitals and clinics that treat these conditions. While no specific customer names are disclosed in the filing the target audience includes individuals seeking treatment for neuropsychiatric disorders and the medical institutions that prescribe antipsychotic therapies.